Sermonix Launches Phase 2 Trial Testing Lasofoxifene in Advanced Breast Cancer Patients with ER Mutations

Sermonix Launches Phase 2 Trial Testing Lasofoxifene in Advanced Breast Cancer Patients with ER Mutations
Sermonix is launching a Phase 2 trial to determine if its lead investigational medicine lasofoxifene is better than Faslodex (fulvestrant) at delaying disease progression or death in breast cancer patients who have a mutation in the estrogen receptor gene ESR1. The open-label, randomized, multicenter trial will include 100 postmenopausal women with locally advanced or metastatic ER-positive/HER2-negative breast cancer. Recruitment will take place across 27 sites in the U.S. “Sermonix is developing lasofoxifene as a personalized medicine treatment for patients with ER+ metastatic breast cancer that have progressed after endocrine and other therapies,” David Portman, Sermonix's CEO, said in a press release. “We look forward to seeing how it performs in the Phase 2 trial versus fulvestrant.” Therapies targeting the estrogen receptor (ER), such as Faslodex, are a mainstay in the treatment of ER-positive breast cancer. But despite initial responses, a large number of patients becomes resistant to treatment by acquiring ER mutations. Lasofoxifene is a selective estrogen receptor modulator approved in Lithuania and Portugal under the brand name Fablyn for the prevention and treatment of osteoporosis
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.